Status:

COMPLETED

Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis

Lead Sponsor:

Novartis

Conditions:

Atopic Dermatitis

Eligibility:

All Genders

2-16 years

Phase:

PHASE3

Brief Summary

Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of Pimecrolimus cream will be evaluated in Japanese pediat...

Eligibility Criteria

Inclusion

  • \- Patients who had completed the core study and whose participation in this study was considered appropriate as judged by the investigator
  • Patients whose guardians have given written informed consent to participation in this study

Exclusion

  • \- Patients who failed in treatment compliance in the core study
  • Patients who had a major violation of the protocol in the core study

Key Trial Info

Start Date :

May 1 2004

Trial Type :

INTERVENTIONAL

End Date :

June 1 2005

Estimated Enrollment :

240 Patients enrolled

Trial Details

Trial ID

NCT00231998

Start Date

May 1 2004

End Date

June 1 2005

Last Update

December 17 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

This study is not being conducted in the United States

Various Cities, Japan

Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis | DecenTrialz